Heru Pradjatmo
Overview
Explore the profile of Heru Pradjatmo including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
33
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Putra A, Gerwindrawan A, Budiono E, Purwanto Utomo B, Afifah N, Sumpono A, et al.
Case Rep Oncol
. 2024 Oct;
17(1):1194-1200.
PMID: 39474546
Introduction: Cancers of unknown primary (CUPs) present a diagnostic challenge as their origin is unidentified at diagnosis. Massive pleural effusion (MPE), indicative of lung metastasis in CUP, categorizes the condition...
2.
Putri H, Novianti P, Pradjatmo H, Haryana S
Oncol Lett
. 2024 Aug;
28(4):491.
PMID: 39185494
Ovarian cancer (OC) poses a significant health risk to women worldwide, with late diagnoses and chemotherapy resistance leading to high mortality rates. Despite several histological subtypes, the primary challenge remains...
3.
Ngadikun , Pradjatmo H, Nugroho K, Pasala M, Prasetyastuti
J Cancer
. 2023 Aug;
14(12):2173-2180.
PMID: 37576394
Erythrocyte sedimentation rate order (ESRO), platelet-lymphocyte ratio (PLR), red cell distribution width (RDW), and neutrophil-lymphocyte ratio (NLR) are hematological parameters that reflect the presence of biomarkers in epithelial ovarian cancer...
4.
Fahmi M, Pradjatmo H, Astuti I, Nindrea R
Asian Pac J Cancer Prev
. 2021 Feb;
22(2):315-323.
PMID: 33639643
Objectives: The value of cytokines as epithelial ovarian cancer (EOC) prognostic factors has been widely investigated. This study aimed to determine the role of single cytokine as a biomarker prognosis...
5.
Pradjatmo H
Asian Pac J Cancer Prev
. 2016 May;
17(4):1881-6.
PMID: 27221870
Background: CA125 is very helpful in treatment monitoring and detection of epithelial ovarian cancer (EOC) recurrence. However there is controversy as to its accuracy and optimal usage. What is the...
6.
Pradjatmo H
Asian Pac J Cancer Prev
. 2016 Jan;
16(18):8599-604.
PMID: 26745123
Ovarian cancer is the main cause of mortality in gynecological malignancy and extensive studies have been conducted to study the underlying molecular mechanisms. The BRCA2 gene is known to be...
7.
Pradjatmo H, Dasuki D, Dwianingsih E, Triningsih E
Asian Pac J Cancer Prev
. 2015 Apr;
16(6):2441-5.
PMID: 25824778
Background: Several risk factors leading to malignant transformation of hydatidiform moles have been described previously. Many studies showed that prophylactic chemotherapy for high risk hydatidiform moles could significantly decrease the...
8.
Pradjatmo H, Dasuki D, Anwar M, Mubarika S, Harijadi
Asian Pac J Cancer Prev
. 2014 Nov;
15(21):9479-85.
PMID: 25422243
Background: Cancer initiation and progression are controlled by genetic and epigenetic events. One epigenetic process which is widely known is DNA methylation, a cause of gene silencing. If a gene...
9.
Koh S, Huak C, Lutan D, Marpuang J, Ketut S, Budiana N, et al.
J Gynecol Oncol
. 2012 Jul;
23(3):175-81.
PMID: 22808360
Objective: To determine the predictive accuracy of the combined panels of serum human tissue kallikreins (hKs) and CA-125 for the detection of epithelial ovarian cancer. Methods: Serum specimens collected from...